Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Decapeptide-12

Lumixyl peptide, Skin lightening peptide

A synthetic decapeptide that acts as a tyrosinase inhibitor to reduce melanin production and treat skin hyperpigmentation.

Quick Stats
Studies 6
Trials 0
Formula C65H90N18O17
Clear All
Utility 4
pubmed Jun 1, 2013

Open-label evaluation of a novel skin brightening system containing 0.01% decapeptide-12 in combination with 20% buffered glycolic acid for the treatment of mild to moderate facial melasma.

Ramírez. Sandra P SP; Carvajal. Alfonso C AC; Salazar. Juan C JC; Arroyave. Gladys G; Flór...

A 16‑week open‑label study in 33 Hispanic women with mild‑to‑moderate melasma found that a skin‑brightening routine containing a 0.01% decapeptide‑12 cream, an antioxidant cleanser, a 20% buffered glycolic‑acid lotion, and SPF 30 sunscreen was safe and cut the melasma severity score by about 60%.

Utility 4
pubmed Jul 6, 2021

Enhanced skin retention and permeation of a novel peptide via structural modification, chemical enhancement, and microneedles.

Chen. Jungen J; Bian. Junxing J; Hantash. Basil M BM; Albakr. Lamyaa L; Hibbs. David E DE; Xiang. Xi...

Researchers improved a skin‑lightening peptide (decapeptide‑12) by attaching a fatty (palmitate) chain, which makes it more oil‑friendly and helps it stay in the skin longer. Adding common skin‑penetration boosters like oleic acid or menthol helped the modified peptide get deeper, while tiny microneedle patches helped the original peptide but not the boosters. The combined tweaks could let DIY users achieve therapeutic levels of the peptide in skin without needing prescription drugs.

Utility 3
pubmed Dec 1, 2018

Efficacy of Trifecting<sup>&#xae;</sup> Night Cream, a Novel Triple acting Skin Brightening Product: A Double-blind, Placebo-controlled Clinical Study.

Jiang. Lily L; Hino. Peter D PD; Bhatia. Ashish A; Stephens. Thomas J TJ; Jimenez. Felipe F

A 28‑week double‑blind study tested a night cream (Trifecting® Night Cream 1.0) that contains decapeptide‑12 on women with moderate‑to‑severe melasma, sun spots, and eye‑area wrinkles. The cream was applied nightly for 24 weeks, then stopped for four weeks. Participants using the cream showed better improvement in skin dark spots, melasma, and fine lines than those who only used cleanser and sunscreen, and the benefits lasted at least a month after stopping.

Utility 3
pubmed Mar 8, 2012

Open-label evaluation of the skin-brightening efficacy of a skin-brightening system using decapeptide-12.

Kassim. Andrea T AT; Hussain. Mussarrat M; Goldberg. David J DJ

A small open‑label study found that a skin‑brightening system containing decapeptide‑12, used together with a cleanser, moisturizer and sunscreen, noticeably reduced facial hyperpigmentation over 24 weeks. About two‑thirds of participants saw their skin tone improve from moderate or severe damage to mild or clear, and the treatment was well tolerated with few side effects.